Search

Your search keyword '"Receptors, Thrombin"' showing total 2,915 results

Search Constraints

Start Over You searched for: Descriptor "Receptors, Thrombin" Remove constraint Descriptor: "Receptors, Thrombin"
2,915 results on '"Receptors, Thrombin"'

Search Results

1. Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis.

2. Discovery of 2,3-Dihydro[1,4]dioxino[2,3- g ]benzofuran Derivatives as Protease Activated Receptor 4 (PAR4) Antagonists with Potent Antiplatelet Aggregation Activity and Low Bleeding Tendency.

3. PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design

4. Supplementation with omega‐3 or omega‐6 fatty acids attenuates platelet reactivity in postmenopausal women

5. Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis.

6. MicroRNA-26a alleviates tubulointerstitial fibrosis in diabetic kidney disease by targeting PAR4.

8. Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4

9. Neutrophil cathepsin G proteolysis of protease-activated receptor 4 generates a novel, functional tethered ligand

10. Triggering receptor expressed on myeloid cells (TREM) like transcript-1 (TLT-1) reveals platelet activation in preeclampsia

11. An optimized agonist peptide of protease-activated receptor 4 and its use in a validated platelet-aggregation assay

12. Targeting PAR4 to Reduce Atherosclerosis.

13. Isolation of Proteasome-Trapped Peptides (PTPs) for Degradome Analysis

14. Q94 is not a selective modulator of proteinase-activated receptor 1 (PAR1) in platelets

15. Disruption of the biological activity of protease‐activated receptors2/4 in adults rather than children in <scp>SARS CoV</scp> ‐2 virus‐mediated mortality in <scp>COVID</scp> ‐19 infection

16. Enhanced endothelial barrier function by monoclonal antibody activation of vascular endothelial cadherin

17. Drupin, a thrombin‐like protease prompts platelet activation and aggregation through protease‐activated receptors

18. Placental thromboinflammation impairs embryonic survival by reducing placental thrombomodulin expression

19. Identification of a Distinct Platelet Phenotype in the Elderly: ADP Hypersensitivity Coexists With Platelet PAR (Protease-Activated Receptor)-1 and PAR-4-Mediated Thrombin Resistance

20. The domino effect triggered by the tethered ligand of the protease activated receptors

21. Par-4 activation restrains EMT-induced chemoresistance in PDAC by attenuating MDM-2

22. Antagonism of Protease-Activated Receptor 4 Protects Against Traumatic Brain Injury by Suppressing Neuroinflammation via Inhibition of Tab2/NF-κB Signaling

23. Protease-activated receptor 4 causes Akt phosphorylation independently of PI3 kinase pathways

24. Probing the epigenetic signatures in subjects with coronary artery disease

25. Molecular basis for activation and biased signaling at the thrombin-activated GPCR proteinase activated receptor-4 (PAR4)

26. Corrigendum to 'TERT and Akt Are Involved in the Par-4-Dependent Apoptosis of Islet β Cells in Type 2 Diabetes'

27. Expression and Purification of Protease-Activated Receptor 4 (PAR4) and Analysis with Histidine Hydrogen–Deuterium Exchange

28. Discovery of 7, 4'-dimethoxy-3-hydroxyflavone as a protease-activated receptor 4 antagonist with antithrombotic activity and less bleeding tendency in mice

29. Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy

30. Inhibitors of protease-activated receptor 4 (PAR4): a review of recent patents (2013-2021)

31. Quantification of platelet function - a comparative study of venous and arterial blood using a novel flow cytometry protocol

32. Epigenetic Regulation of

33. Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis

34. Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemia

35. New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans

36. PAR4-Mediated PI3K/Akt and RhoA/ROCK Signaling Pathways Are Essential for Thrombin-Induced Morphological Changes in MEG-01 Cells

37. Tirofiban potentiates agonist-induced platelet activation and degranulation, despite effectively inhibiting aggregation

38. The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population

39. Blocking protease-activated receptor 4 alleviates liver injury induced by brain death

40. Genetic deletion of platelet PAR4 results in reduced thrombosis and impaired hemostatic plug stability

42. Platelet function testing using the Multiplate analyzer after administration of aspirin in Aachen minipigs

43. Proteinase-activated receptors regulate intestinal functions in a segment-dependent manner in rats

44. Hypoxia Modulates Platelet Purinergic Signalling Pathways

45. Differential Effects of Platelets Selectively Activated by Protease-Activated Receptors on Meniscal Cells

46. Thrombin Induces Secretion of Multiple Cytokines and Expression of Protease-Activated Receptors in Mouse Mast Cell Line

47. Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel

48. Nandrolone decanoate and resistance exercise affect prostate morphology and hormone receptor interface in adult rats with implications for the aging process

49. Spinal macrophage migration inhibitory factor and high mobility group box 1 mediate persistent bladder pain

50. Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog

Catalog

Books, media, physical & digital resources